Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke (ACTION)

This study is currently recruiting participants.
Verified March 2014 by Biogen Idec
Information provided by (Responsible Party):
Biogen Idec
ClinicalTrials.gov Identifier:
First received: September 30, 2013
Last updated: March 7, 2014
Last verified: March 2014

The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) BG00002 reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in subjects with acute ischemic stroke when given at ≤6 hours or at >6 to ≤9 hours from when they were last known normal (LKN).

The secondary objectives of this study in this study population are as follows: To assess the efficacy of BG00002 on change in infarct volume from Baseline to Day 30; To assess efficacy of BG00002 on change in infarct volume from 24 hours to Day 5 and Day 30; To assess the efficacy of BG00002 on clinical measures of stroke outcome; To assess the safety of BG00002 in subjects with acute ischemic stroke

Condition Intervention Phase
Acute Ischemic Stroke
Biological: BG00002
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke

Resource links provided by NLM:

Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • Change in Infarct Volume from Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR]) [ Time Frame: Day 5 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Infarct Volume From Baseline (DWI) to Day 30 (FLAIR) [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
  • Change in Infarct Volume From 24 hours (DWI) to Day 5 and Day 30 (FLAIR) [ Time Frame: Up to Day 30 ] [ Designated as safety issue: No ]
  • Change in National Institute of Health Stroke Scale (NIHSS) Score from Baseline to 24 hours, Day 5, Day 30, and Day 90 [ Time Frame: Up to Day 90 ] [ Designated as safety issue: No ]
  • Modified Rankin Scale (mRS) distribution at Day 5, Day 30, and Day 90 [ Time Frame: Up to Day 90 ] [ Designated as safety issue: No ]
  • Barthel Index at Day 5, Day 30, and Day 90 [ Time Frame: Up to Day 90 ] [ Designated as safety issue: No ]
  • Number of subjects who experience Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to Day 90 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 200
Study Start Date: January 2014
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BG00002
a single dose of BG00002
Biological: BG00002
300 mg single intravenous injection
Other Name: Natalizumab
Placebo Comparator: Placebo
a single dose of placebo
Drug: Placebo
single intravenous injection


Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Diagnosis of acute ischemic stroke.
  • Score of ≥6 points on the National Institute of Health Stroke Scale (NIHSS) at Screening.
  • At least 1 acute infarct with largest diameter of more than 2 cm on Baseline brain diffusion-weighted imaging (DWI).
  • Participants who have received reperfusion therapy may be eligible to participate but must meet all eligibility criteria and perform the Baseline study magnetic resonance imaging (MRI) after reperfusion therapy has been completed.
  • Subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for at least 3 months after their dose of study treatment.

Key Exclusion Criteria:

  • Presence of any intracranial hemorrhage (ICH) on head computed tomography (CT) or non-petechial ICH on screening MRI.
  • Stroke isolated to the brainstem.
  • Presence of coma
  • Expected to die OR unable to be evaluated within 5 days.
  • Hypotension requiring the use of intravenous (IV) vasopressor support or systolic blood pressure <90 mmHg at the time of randomization.
  • Known prior treatment with natalizumab.
  • Immunocompromised subjects, as determined by the Investigator.
  • History of progressive multifocal leukoencephalopathy (PML).
  • Contraindications to MRI, e.g., implanted pacemaker or other contraindicated implanted metal devices, history of or risk for side effects from gadolinium, or claustrophobia that cannot be medically managed.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01955707

Contact: Biogen Idec Investigator clinicaltrials@biogenidec.com

United States, California
University of California San Diego Medical Center Not yet recruiting
San Diego, California, United States, 92103
United States, Minnesota
Minneapolis Clinic of Neurology Ltd Not yet recruiting
Golden Valley, Minnesota, United States, 55422
United States, Missouri
University of Kansas Medical Center Not yet recruiting
Kansas City, Missouri, United States, 66160
United States, New York
Montefiore Medical Center PRIME Recruiting
Bronx, New York, United States, 10467
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
United States, Ohio
Akron General Medical Center Not yet recruiting
Akron, Ohio, United States, 44307
Miami Valley Hospital Not yet recruiting
Dayton, Ohio, United States, 45409
United States, Oregon
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Providence Stroke Center Not yet recruiting
Portlnad, Oregon, United States, 97225
United States, Pennsylvania
University of Pennsylvania Hospital Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Klinikum Altenburger Land Not yet recruiting
Altenburg, Germany, 4600
Neurologishce Klinik Bad Neustadt/Saale Not yet recruiting
Bad Neustadt, Germany, 97616
Klinikum Idar-Oberstein GmbH Not yet recruiting
Idar-Oberstein, Germany, 55743
Hospital Clinic I Provincial de Barcelona Not yet recruiting
Barcelona, Spain, 8036
Hospital Universitari Vall d'Hebron Not yet recruiting
Barcelona, Spain, 8035
Hospital Universitario Virgen del Rocio Not yet recruiting
Sevilla, Spain, 41013
Sponsors and Collaborators
Biogen Idec
Study Director: Medical Director Biogen Idec
  More Information

No publications provided

Responsible Party: Biogen Idec
ClinicalTrials.gov Identifier: NCT01955707     History of Changes
Other Study ID Numbers: 101SK201, EUDRA CT NO: 2013‐001514‐15
Study First Received: September 30, 2013
Last Updated: March 7, 2014
Health Authority: Spain: Spanish Agency of Medicines
Germany: Federal Institute for Drugs and Medical Devices
United States: Food and Drug Administration

Additional relevant MeSH terms:
Cerebral Infarction
Pathologic Processes
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Brain Infarction
Brain Ischemia

ClinicalTrials.gov processed this record on April 17, 2014